Trial · NCT01346293
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Booster Response to the Pertussis Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 (pre-vaccination) and Day 28 post-vaccination | Anti-pertussis booster responses were assessed in the Per-Protocol Analysis Set. | Participants | NUMBER |
| PRIMARY | Geometric Mean Concentrations of the Pertussis Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 (pre-vaccination) and Day 28 post-vaccination | Geometric mean concentrations were assessed in the Per-Protocol Analysis Set. | Titers | GEOMETRIC_MEAN |
| PRIMARY | Number of Participants With Booster Response to Tetanus and Diphtheria Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 (pre-vaccination) and Day 28 post-vaccination | Anti-Tetanus and anti-diphtheria booster responses were assessed in the Per-Protocol Analysis Set. | Participants | NUMBER |
| PRIMARY | Geometric Mean Concentrations of the Tetanus and Diphtheria Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 (pre-vaccination) and Day 28 post-vaccination | Geometric mean concentrations of tetanus and diptheria antibodies were assessed in the Per Protocol Analysis Set. | Titers | GEOMETRIC_MEAN |
| PRIMARY | Number of Participants With Booster Response to Polio Antigens Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 (pre-vaccination) and Day 28 post-vaccination | Anti-polio booster responses were assessed in the Per-Protocol Analysis Set. | Participants | NUMBER |
| PRIMARY | Geometric Mean Concentrations of Polio Antibodies Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 (pre-vaccination) and Day 28 post-vaccination | Geometric mean concentrations of poliovirus antibodies were assessed in the Per-Protocol Analysis Set. | Titers | GEOMETRIC_MEAN |
| OTHER_PRE_SPECIFIED | Number of Participants With Seroprotection Against the Tetanus and Diphtheria Antigens Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 (pre-vaccination) and Day 28 post-vaccination | Seroprotection against tetanus and diphtheria antigens was assessed in the Per-Protocol Analysis Set. | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Number of Participants With Seroprotection Against the Polio Antigens Before and Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 (pre-vaccination) and Day 28 post-vaccination | Seroprotection (antibody titers ≥1:8 dilution) against polio antigens was assessed in the Per-Protocol Analysis Set. | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Number of Participants With Booster Response to the Polio Antigens Following Vaccination With Inactivated Poliovirus (IPV) Vaccine as a 4th or 5th Dose | Day 0 (pre-vaccination) and Day 28 post-vaccination | Booster responses to polio antigens following IPV vaccine as 4th or 5th dose were assessed in the Per-Protocol Analysis Set. | Participants | NUMBER |
| OTHER_PRE_SPECIFIED | Summary of Anti-Polio Geometric Mean Titers in Participants That Received Inactivated Poliovirus (IPV) Vaccine as a 4th and 5th Dose | Day 0 (pre-booster vaccination) and Day 28 post-booster vaccination | Anti-Polio geometric mean titers were assessed in the Per-Protocol Analysis Set. | Titers | GEOMETRIC_MEAN |
| OTHER_PRE_SPECIFIED | Number of Participants Reporting Solicited Injection-site and Systemic Reactions Following Vaccination With Either DTaP-IPV or DAPTACEL® + IPOL® Vaccine | Day 0 up to Day 28 post-final vaccination | Solicited injection-site and systemic reactions were assessed in the Safety Analysis Set. | Participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01346293/outcomes